-
Iran's economic ties to Dubai hard to break despite war
-
NFL Week 1 Predictions: Dave Blezow’s Best Bets Against the Spread for Every Game
-
iPhone 18預購後出現可疑扣款 四間銀行調查未授權交易
-
Alabama Legislature Passes Weakened Utility Reform Bill Amid Allegations of Alabama Power Influence
-
《浪花男女》辦特別謝票場 馮志強談票房與導演客串拍攝
-
World Athletics stance on Russia unchanged, says Coe
-
Former captain De Villiers hails 'fantastic' Springboks
-
Can We Predict Volcanic Eruptions Like Weather? Scientists Seek Unified Physics
-
Galaxy Tab S12系列效果圖曝光 Ultra擬配雙鏡頭及瀏海螢幕
-
Macron, Carney to visit French islands after Trump's map post
-
اليورو يستقر في البنوك المصرية وأعلى سعر للبيع 59.85 جنيه
-
بزشكيان يؤكد رفض الاستسلام وسلطات إيران تعلن مقتل شخص في استهداف سفينة
-
حمزة قورقماز يناقش العلاقة بين وضوح المبادئ واحترام الاختلاف
-
فليك يضم حمزة عبد الكريم إلى قائمة برشلونة بعد أربعة أهداف في الإعداد
-
Altman tells Fortune OpenAI will not go public in 2026
-
Myanmar says UN envoy illegitimate ahead of credentials decision
-
China, Russia, India seek economic cooperation at BRICS
-
Philippine rescuers pull more victims from charred ferry
-
الأرصاد السعودية تتوقع سيولاً وأمطاراً رعدية في خمس مناطق
-
ستاندرد آند بورز تثبت تصنيف السعودية عند A+
-
دول عربية ومنظمات تدين استهداف خط أنابيب في السعودية
-
Crash and burn: Pakistan cricket at a new low after England humiliation
-
One dead, 102 rescued from stricken ferry off Indonesia's Java
-
'Second life': Nepal tunnel survivor recalls ordeal
-
Garcia keeps WBC welterweight title by stopping Benn
-
Hong Kong homes flattened for US$28 bn high-tech hub
-
Lights out in Laos as electricity exports surge
-
'Be careful what you wish for': 'Obsession' director and star reflect on success
-
'This is the test': All eyes on US Fed to tackle high inflation
-
Messi scores but Miami held by Nashville
-
Scars of Marawi siege linger as Philippines poll nears
-
US Open champ Rybakina on top of world after injury scare
-
Trump turns to golf, family business on Irish visit's second day
-
Rybakina reigns serene as new world number one
-
Best Online Gold Dealers in USA 2026 Rankings Released By Experts
-
Defiant Sabalenka motivated by US Open defeat
-
South Africa defeat New Zealand 43-28 to complete 3-1 series victory
-
Houthis say hit Saudi base after renewed fighting with Yemeni govt forces
-
Rybakina triumphs in US Open, denies Sabalenka three-peat
-
Japanese floating parking platform is designed to lift cars above floodwater
-
Mini 1998 GT pairs 161-hp engine with John Cooper Works chassis hardware
-
GTA VI draws political criticism online as preorder estimates exceed five million
-
Anthropic details Claude misuse as US targets major illicit online marketplace
-
Steven Strogatz weighs AI mathematics advances and their consequences for researchers
-
Fifth Circuit upholds dismissal of Jackson residents' constitutional water claims
-
KFF journalists discuss opioid funds, suicide prevention and gaps in care
-
Winston County trash-debt prosecutions face challenge from civil-rights lawyers
-
Roadless Rule repeal proposal raises concerns over Midwest forests and fire risk
-
Akron fan's honorary play-calling stint ends with opening-drive fumble
-
Louisiana's developing roster faces USC as Trojans enter as heavy favorites
Abortion pill under threat in Texas court case
US abortion opponents are hoping for a national ban on a widely used abortion pill when their lawsuit against government drug regulators is argued Wednesday in the Texas court of a deeply conservative judge believed to be sympathetic to their cause.
Galvanized after the US Supreme Court ended the nationwide right to abortion last June, anti-abortion forces are now targeting the prescription drug mifepristone in their campaign to win a total ban on the practice.
The suit against the US Food and Drug Administration (FDA) aims at a pill involved in 53 percent of all abortions in the United States, or more than a half-million every year.
While the FDA has never been challenged like this before on its approval of a drug that has proven safe and effective, the plaintiffs, a coalition of anti-abortion groups, believe they can win a national freeze on distribution of mifepristone.
Presiding over the case in federal court in Amarillo, Texas will be Judge Matthew Kacsmaryk, a deeply conservative Christian with a personal history of opposition to abortion and a court record of favoring right-wing causes.
The case ended up in his court via what critics call "judge-shopping," in which plaintiffs take legal action in a district where the judge has a history of rulings that support their case.
- Record of safety -
One component of a two-drug regimen used for medication abortion, mifepristone can be used in the United States up to 10 weeks of pregnancy.
It has a long safety record, and the FDA estimates 5.6 million Americans have used it to terminate pregnancies since it was approved.
But the Alliance Defending Freedom, a Christian advocacy group, sued the FDA saying the approval of mifepristone "disavow(ed)" science, "ignored" potential health impacts and "disregarded" the complications that can arise with its use.
"The FDA failed America's women and girls when it chose politics over science and approved chemical abortion drugs for use in the United States," they said.
The FDA has urged the judge to reject the request.
"The public interest would be dramatically harmed by effectively withdrawing from the marketplace a safe and effective drug that has lawfully been on the market for 22 years," it said.
- Already banned in some states -
Currently, some 15 states have laws restricting access to mifepristone by requiring a physician provide it, according to the Guttmacher Institute, a reproductive health policy and research group. Abortion care has halted in another 13 states after the Supreme Court overturned the long-established constitutional right last June.
The Texas suit seeks to block mifepristone nationally by overturning the FDA's approval of the drug, and asks Kacsmaryk to first suspend the approval via injunction -- an effective ban -- while the lawsuit proceeds through his court.
Abortion rights groups say a ruling blocking mifepristone would be as earth-shaking as the Supreme Court's ruling last year.
"Access to medication abortion would end across the country -- even in those states where abortion rights are protected," the Center for Reproductive Rights said.
If Kacsmaryk does rule for a temporary ban on mifepristone, the FDA would likely immediately appeal it, on the basis of the drug's history and its own authority to regulate pharmaceuticals.
But abortion rights advocates were preparing for the worst.
"It seems unbelievable that a lone judge in Texas could make a ruling that would impact a product that has been FDA approved and safely marketed for more than two decades," said Elisa Wells, co-founder of Plan C, which helps people access medical abortions.
A.Ruiz--AT